



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board

Ref:

Gynaecology Rapid Access Service (GRAS) for Suspected Endometrial Cancer Guideline

INITIATED BY: Sr. C L Davies / Mr S.R Watermeyer

APPROVED BY: Gynae Forum

DATE APPROVED: January 2023

VERSION: 1.0

OPERATIONAL DATE:

DATE FOR REVIEW: 3 years from date of approval or if any legislative or operational changes require

DISTRIBUTION: Consultants Obs/gynae
Head of midwifery/Gynaecology
Senior Nurse
Gynae Forum

FREEDOM OF INFORMATION STATUS: Open

Guidelines Definition

Clinical guidelines are systemically developed statements that assist clinicians and patients in making decisions about appropriate treatments for specific conditions.

They allow deviation from a prescribed pathway according to the individual circumstances and where reasons can be clearly demonstrated and documented.

Minor Amendments

If a minor change is required to the document, which does not require a full review please identify the change below and update the version number.

Type of change	Why change made	Page number	Date of change	Version 1 to 1.1	Name of responsible person

CONTENTS

<u>Guidelines Definition</u>	i
<u>Minor Amendments</u>	i
1. Introduction.....	3
2. Audit and Research.....	3
3. Roles and Responsibilities.....	5
4. Referrals.....	5
5. Rapid Access Clinic.....	6
6. References.....	6
Appendix A- PMB pathway algorithm.....	9
Abbreviations.....	11

1. Introduction

Endometrial Cancer (E.C) is the fourth most common gynaecological malignancy in the UK and Endometrial Hyperplasia can be a precursor (British Gynaecological Cancer Society 2021 (BGCS)).

Post-Menopausal Bleeding (PMB) is defined as a vaginal bleed that has occurred more than one year since a woman's last menstrual bleed (BGCS 2021). PMB is the most common presentation to give suspicion of EC, but others can include intermenstrual bleeding (IMB), unscheduled bleeding on hormone replacement therapy (HRT), post-coital bleeding (PCB) or an incidental finding on Ultrasound Scan (USS) (Royal College of Gynaecologists (RCOG) 2016).

It is the aim within Cwm Taf Morgannwg UHB to provide an effective and efficient out-patient Hysteroscopy/Gynaecology service to diagnose and treat EC promptly, as recommended by RCOG, British Society of Gynaecology Endoscopists (BSGE), National Institute of Clinical Excellence (NICE) and The Welsh Cancer Network (WCN).

This document aims to standardise the referral to treatment process across the Health Board for suspected E.C's.

2. Audit and Research

NHS Wales Health Collaborative (review 2021) state that all efforts should be made for Urgent Suspected Cancer (USC) referrals to have completed their diagnostic procedures, within 28 days from the point of suspicion and the treatment pathway should be commenced within 21 days of the decision to treat (< 62 days for the first definitive treatment from the point of suspicion).

NICE (2015, updated 2021) state that referrals for suspected EC should be seen within two weeks.

Previous internal audits into Hysteroscopy waiting times have indicated that compliance with the above targets were sub-optimal, hence the requirement for a Gynaecology Rapid Access Service (GRAS) to ensure timely review and adequate diagnostic facility.

According to the BGCS (2021), Trans-vaginal Ultra-sound should be employed as an initial investigation for women presenting with PMB. In such women, if the endometrial thickness (ETT) is less than 4mm (in the absence of any irregularity such as the presence of fluid, disparity of ETT within the endometrial echo) no further investigation is required (pending a normal speculum examination). However, in the presence of recurrent PMB, further investigation needs to be undertaken. Hanegem et al (2016) support the requirement to perform Hysteroscopy with an ETT $> / = 4\text{mm}$

Along with this, the BGCS (2021) also state that an incidental finding (i.e., no PMB) of a 'thickened endometrium' on USS on a woman not using HRT do not necessarily require a Hysteroscopy or endometrial biopsy if reported as $< / = 10\text{mm}$. Recurrent PMB will require a hysteroscopy irrelevant of their USS results (Appendix A).

In addition, a well-designed decision analysis calculated that post-menopausal patients without vaginal bleeding, with an ETT $> 11\text{mm}$ had an endometrial cancer risk of 6.7%, which is a similar risk to post -menopausal women with bleeding and an ETT of $> 5\text{mm}$ (Feldman and Levine 2022). They also conclude that fluid in the cavity with an ETT $< 3\text{mm}$ can be disregarded.

Risk factors that pre-dispose women to endometrial carcinoma are listed in appendix A and clinicians are encouraged to use their clinical judgement when deciding if further investigation is warranted, aside from the results of the USS.

3. Roles and Responsibilities

When a patient presents with any of the discussed presenting symptoms, the primary healthcare professional should undertake a full abdominal and pelvic examination, including speculum examination of the cervix. The clinician should obtain a detailed account of the presenting symptoms, a full drug history (including use of HRT, oral contraceptive pill, tamoxifen etc), and a Gynaecological history (early menarche/late menopause, known endometrial hyperplasia, parity). Medical, family and surgical history may be relevant (obesity, treatment for breast cancer, diabetes mellitus, hypertension, and Lynch syndrome) (BGCS 2021).

Transvaginal Scan (TVS) with measurement of ETT should be employed as initial investigation for women presenting with PMB or IMB. The strategy with TVS within 10 days, +/- Hysteroscopy +/- Endometrial BX (appendix A), is the most effective method for the UK population (BGCS 2021).

Women on HRT for < 4-6 months, should be managed by the G.P to consider altering the Progestogen element i.e. inserting the Mirena IUS / altering the progestogen dose (British Menopause Society (BMS) 2021)

For women on HRT > 4-6 months, they should follow the standard PMB pathway (Appendix A) (NICE 2019).

It should be noted that women who are post-menopausal should be on Continuous Combined HRT which confers a lower risk of EC, compared with the general population (BMS 2021). However, the use of sequential HRT for > 5 years, increases the risk of EH and EC.

4. Referrals:

All women with PMB or suspicious vaginal bleeding should be referred into the GRAS service.

A Gynaecologist or Nurse Hysteroscopist will triage referrals to determine if the patient is to be seen in Gynaecology Out-patient Clinic (GOPD) or GRAS, based on the information provided by the Primary Care Practitioner and following the algorithm attached (Appendix A).

If there is no scan attached to the USC referral, the triaging clinician will request for the woman to be allocated to GRAS, to have an USS performed +/- Hysteroscopy depending on the USS findings.

5. Gynaecology Rapid Access Service (Urgent Suspected Cancer)

GRAS facility includes :-

- The woman receiving a USS of pelvis (if not already performed by the GP)
- +/- an endometrial biopsy, based on USS report and symptoms
- +/- referral for a Hysteroscopy, based on USS report and symptoms
- +/- referral to Colposcopy / Vulvoscopy if a suspicious cervix / vulval lesion is noted on speculum examination.

6. References

- British Gynaecological Cancer Society (2021) Uterine Cancer Guideline. BGCS/RCOG
- British Menopause Society (2021). Progestogens and Endometrial Protection. BMS, Tools for Clinicians.
- Feldman S and Levine D (2022). Overview of the Evaluation of the Endometrium for malignant or pre-malignant disease. <https://www.uptodate.com/contents/overview-of-the-evaluation-of-the-endometrium-for-malignant-or-premalignant-disease/contributors>


- Hanegem, Breijer C, Slockers A.C, Zafarmand M.H, Geomini PMAJ, Catshoek R, Pijnenborg JMA, Van der Voet L.F, Dijkhuizen FPHLJ , Van Hoecke GCR, Reesink-Peters N, Veersema S, Van Hooff MHA, Van Kesteren PJM, Huirne JA, Opmeer B.C, and Bongers M.Y (2016) Diagnostic workup for postmenopausal bleeding: a randomised controlled trial. BJOG. An International Journal of Obstetrics and Gynaecology DOI: 10.1111/1471-0528.14126.
<https://obgyn.onlinelibrary.wiley.com/doi/epdf/10.1111/1471-0528.14126>
- NHS Wales Health Collaborative (2020) National Optimal Pathway for Endometrial Cancer. *Single Cancer Pathway.*
- National Institute for Health and Care Excellence (2015) (updated 2021) Suspected Cancer: Recognition and Referral. NICE Guideline NG 12.
- National Institute for Health and Care Excellence (2015) (updated 2019) Menopause: Diagnosis and Management. NICE Guideline NG 23.
- Royal College of Obstetrics and Gynaecology (2016) Management of Endometrial Hyperplasia. Green top Guideline No. 67 RCOG


Other useful references

- Bertelli G, Hall E, Ireland E et al. Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen. Ann Oncol 2010; 21:498-505.

- British Society of Gynaecology Endoscopy (2011) Best Practice in Out Patient hysteroscopy. Green Top Guideline 59. BSGE/RCOG
- Gupta JK, Chien PF, Voit D et al. Ultrasonographic endometrial thickness for diagnosing endometrial pathology in women with postmenopausal bleeding: a meta-analysis. *Acta Obstet Gynecol Scand* 2002; 81:799-816.
- NHS Kernow Commissioning Group (2017) Endometrial Thickening. Asymptomatic endometrial thickening in post-menopausal women
- Opmeer BC, Van Doorn HC, Heintz AP et al. Improving the existing diagnostic strategy by accounting for characteristics of the women in the diagnostic work up for postmenopausal bleeding. *BJOG* 2007; 114:51-58.
- Otify, M., Fuller, J., Ross, J., Shaikh, H. and Johns, J. (2015) Endometrial pathology in the postmenopausal woman—an evidence based approach to management. *The Obstetrician & Gynaecologist* 17(1) pp.29-38.
- Smith-Bindman R, Kerlikowske K, Feldstein VA et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. *JAMA* 1998; 280:1510-1517.
- Van Hanegem N., Prins MM, Bongers MY et al. The accuracy of endometrial sampling in women with postmenopausal bleeding: a systematic review and meta-analysis. *Eur J Obstet Gynecol Reprod Biol* 2016; 197:147-155.

Appendix A





Abbreviations Used:

PMB	Post-Menopausal Bleeding
Endo Bx	Endometrial Biopsy
Hyst	Hysteroscopy
ETT	Endometrial Thickness
LA	Local Anaesthesia
GA	General Anaesthetic
BX	Biopsy
HRT	Hormone Replacement Therapy
USS	Ultrasound Scan
PV	Per Vagina
RCOG	Royal College of Obstetrics & Gynaecology
MRI	Magnetic Resonance Imaging
MDT	Multi-Disciplinary Team
CC HRT	Continuous Combined Hormone Replacement Therapy
E2	Oestrogen
BMS	British Menopause Society
IUS	Intra uterine system
EH	Endometrial Hyperplasia
PCOS	Polycystic Ovarian Syndrome